- Home
- NUVL vs UFPI Comparison
NUVL vs UFPI Comparison
Compare NUVL & UFPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- UFPI
- Stock Information
- Founded
- NUVL 2017
- UFPI 1955
- Country
- NUVL United States
- UFPI United States
- Employees
- NUVL N/A
- UFPI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- UFPI Forest Products
- Sector
- NUVL Health Care
- UFPI Basic Materials
- Exchange
- NUVL Nasdaq
- UFPI Nasdaq
- Market Cap
- NUVL 6.7B
- UFPI 6.6B
- IPO Year
- NUVL 2021
- UFPI 1993
- Fundamental
- Price
- NUVL $75.84
- UFPI $116.76
- Analyst Decision
- NUVL Strong Buy
- UFPI Strong Buy
- Analyst Count
- NUVL 11
- UFPI 4
- Target Price
- NUVL $112.36
- UFPI $148.00
- AVG Volume (30 Days)
- NUVL 558.9K
- UFPI 377.8K
- Earning Date
- NUVL 02-25-2025
- UFPI 02-18-2025
- Dividend Yield
- NUVL N/A
- UFPI 1.13%
- EPS Growth
- NUVL N/A
- UFPI N/A
- EPS
- NUVL N/A
- UFPI 7.26
- Revenue
- NUVL N/A
- UFPI $6,714,661,000.00
- Revenue This Year
- NUVL N/A
- UFPI N/A
- Revenue Next Year
- NUVL N/A
- UFPI $3.34
- P/E Ratio
- NUVL N/A
- UFPI $16.07
- Revenue Growth
- NUVL N/A
- UFPI N/A
- 52 Week Low
- NUVL $61.80
- UFPI $107.25
- 52 Week High
- NUVL $113.51
- UFPI $141.33
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- UFPI 48.63
- Support Level
- NUVL $69.58
- UFPI $107.25
- Resistance Level
- NUVL $78.18
- UFPI $120.00
- Average True Range (ATR)
- NUVL 3.03
- UFPI 2.56
- MACD
- NUVL 0.04
- UFPI 1.30
- Stochastic Oscillator
- NUVL 50.40
- UFPI 74.59
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction.